SLC5A2 and hydrops fetalis: In such a close relationship between T2DM and HF, sodium-glucose cotransporter 2 inhibitors (SGLT2i) have proven to be a powerful tool for the treatment of both pathologies, to the point that the latest AHA/ACC/HFSA guidelines recommend their use in stage A HF (21).